Sirdalud

Sirdalud Use In Pregnancy & Lactation

tizanidine

Manufacturer:

Sandoz

Distributor:

Zuellig Pharma
Full Prescribing Info
Use In Pregnancy & Lactation
Pregnancy: Risk Summary: As there is limited experience with the use of Sirdalud in pregnant women, it should not be used during pregnancy unless the benefit clearly outweighs the risk (see Clinical Pharmacology: Toxicology: NONCLINICAL SAFETY DATA under Actions).
Animal data: Reproduction studies performed in rats and rabbits did not show evidence of teratogenicity. In rats, dose levels of 10 and 30 mg/kg/day increased gestation duration. Prenatal and postnatal pup loss was increased and development retardation occurred. At these doses, dams showed marked signs of muscle relaxation and sedation. Based on body surface area, these doses were 2.2 and 6.7 times the maximum recommended human dose of 0.72 mg/kg/day.
Lactation: Risk Summary: Small amounts of tizanidine are excreted in rat milk. Since no human data are available Sirdalud should not be given to women who are breast-feeding.
Females and males of reproductive potential: Pregnancy testing: Sexually-active females of reproductive potential are recommended to have a pregnancy test prior to starting treatment with Sirdalud.
Contraception: Females of reproductive potential should be advised that animal studies have been performed showing Sirdalud to be harmful to the developing fetus. Sexually-active females of reproductive potential are recommended to use effective contraception (methods that result in less than 1% pregnancy rates) when using Sirdalud during treatment and for 1 day after stopping treatment with Sirdalud.
Fertility: Animal Data: No impairment of fertility was observed in male rats at a dose of 10 mg/kg/day and in female rats at a dose of 3 mg/kg/day. Fertility was reduced in male rats receiving 30 mg/kg/day and in female rats receiving 10 mg/kg/day. Based on body surface area, these doses were 6.7 and 2.2 times the maximum recommended human dose of 0.72 mg/kg. At these doses, maternal behavioural effects and clinical signs were observed including marked sedation, weight loss, and ataxia (see Clinical Pharmacology: Toxicology: NON-CLINICAL SAFETY DATA under Actions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in